coronavirus
Project leader: Oxford's #COVID-19 vaccine trial has 50% chance of success
The University of Oxford's COVID-19 vaccine trial has only a 50% chance of success as the coronavirus seems to be fading rapidly in Britain, the professor co-leading the development of the vaccine told the Daily Telegraph newspaper, writes Kanishka Singh. Adrian Hill (pictured), director of Oxford’s Jenner Institute, which has teamed up with drugmaker AstraZeneca Plc to develop the vaccine, said that an upcoming trial, involving 10,000 volunteers, threatened to return “no result” due to low transmission of COVID-19 in the community.
“It’s a race against the virus disappearing, and against time”, Hill told the British newspaper. “At the moment, there’s a 50% chance that we get no result at all.”
The experimental vaccine, known as ChAdOx1 nCoV-19, is one of the front-runners in the global race to provide protection against the new coronavirus causing the COVID-19 pandemic.
Hill’s team began early-stage human trials of the vaccine in April, making it one of only a handful to have reached that milestone.
Share this article:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
-
Middle East3 days agoSecurity realignment inevitable in Middle East after Netanyahu-Trump's war
-
Uzbekistan4 days agoThe Third International Maqom Art Forum and the New Uzbekistan
-
Transport3 days agoBetter enforcement of passenger rights: New EU agreement strengthens protection across all modes of transport
-
Ukraine5 days ago'Ukraine does not need investment out of sympathy': Seyar Kurshutov on the rational case for early entry
